Gain Therapeutics, Inc. reported a net loss of $20.2 million for the fiscal year ending December 31, 2025, a slight decrease from the $20.4 million loss recorded in the previous year. The company's total operating expenses for 2025 were approximately $18.7 million, down from $20.4 million in 2024, primarily due to reduced research and development costs, which fell to $10.2 million from $10.8 million. General and administrative expenses also decreased to $8.5 million from $9.6 million, reflecting lower stock-based compensation and legal fees, although these were partially offset by increased personnel costs.
The company has not yet generated any revenue from product sales, as its lead candidate, GT-02287, is still in clinical trials for the treatment of Parkinson's disease. As of December 31, 2025, Gain Therapeutics had cash and cash equivalents of $20.8 million, an increase from $10.4 million in 2024. However, the company reported substantial doubt about its ability to continue as a going concern, indicating that it will need to raise additional capital to fund operations beyond the first quarter of 2027. The company plans to address its liquidity needs through public and private equity offerings, debt financing, and potential collaborations.
In terms of operational developments, Gain Therapeutics has made significant progress with GT-02287, completing two clinical studies and preparing for a Phase 2 trial expected to begin in the second half of 2026. The Phase 1a study demonstrated that GT-02287 was safe and well-tolerated in healthy participants, while the ongoing Phase 1b study aims to further evaluate its safety and tolerability in Parkinson's patients. The company has also been optimizing its pipeline costs, which contributed to the reduction in research and development expenses.
As of the end of 2025, Gain Therapeutics had 21 employees, with 13 focused on research and development. The company operates in multiple locations, including the United States, Switzerland, Spain, and Australia, and has plans to expand its operations further. The company’s strategic focus remains on advancing its pipeline of small molecule therapeutics using its proprietary Magellan™ platform, which is designed to identify allosteric binding sites on proteins implicated in various diseases.
Looking ahead, Gain Therapeutics faces challenges related to funding, regulatory approvals, and competition in the biotechnology sector. The company is actively seeking additional financing and exploring strategic partnerships to support its development programs. The ongoing geopolitical tensions and macroeconomic conditions, including inflation and supply chain disruptions, may also impact the company's operations and financial performance in the future.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology company developing small molecule therapeutics targeting protein misfolding and dysfunction across neurodegenerative, lysosomal storage, metabolic, and oncology diseases. Utilizing its Magellan® platform, it identifies allosteric binding sites to create highly specific, brain-penetrant drugs. Its pipeline includes candidates for Parkinson’s disease and other neurodegenerative disorders, focusing on restoring enzyme function and addressing unmet medical needs through innovative, mechanism-based therapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.